These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 1589447)

  • 21. Potentiation of antiaggregating effect of prostaglandins by alpha-tocopherol and quercetin.
    Mardla V; Kobzar G; Samel N
    Platelets; 2004 Aug; 15(5):319-24. PubMed ID: 15370103
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of platelet aggregation by 6-keto-PGE1; lack of an effect on cyclic GMP levels.
    Pontecorvo EG; Myers CB; Lippton HL; Kadowitz PJ
    Prostaglandins Med; 1981 May; 6(5):473-83. PubMed ID: 6267636
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stimulatory effects of vascular prostaglandins on the antiaggregatory activities of pentoxifylline acetylsalicylic acid combinations in vitro.
    Weithmann KU; Just M; Schlotte V; Seiffge D
    Vasa; 1989; 18(4):273-6. PubMed ID: 2514520
    [TBL] [Abstract][Full Text] [Related]  

  • 24. On the metabolism of prostaglandin E1 administered intravenously to human volunteers.
    Peskar BA; Cawello W; Rogatti W; Rudofsky G
    J Physiol Pharmacol; 1991 Sep; 42(3):327-31. PubMed ID: 1793892
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Formation of 13,14-dihydro-prostaglandin E1 during intravenous infusions of prostaglandin E1 in patients with peripheral arterial occlusive disease.
    Peskar BA; Hesse WH; Rogatti W; Diehm C; Rudofsky G; Schweer H; Seyberth HW
    Prostaglandins; 1991 Mar; 41(3):225-8. PubMed ID: 1852896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of 6-oxo-prostaglandin E1 on human platelet aggregation in whole blood in-vitro.
    Wilsoncroft PS; Lofts FJ; Griffiths RJ; Moore PK
    J Pharm Pharmacol; 1985 Feb; 37(2):139-41. PubMed ID: 2858551
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of adenosine diphosphate-induced intravascular aggregation of rat platelets in vivo by 6-oxo-prostaglandin E1.
    Oyekan AO; Botting JH
    Prostaglandins; 1987 Sep; 34(3):359-66. PubMed ID: 3324168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of the thiol group inhibitor monobromobimane and other inhibitors on the composition of the platelet cytoskeletal core and its association with glycoprotein IIIa.
    Puszkin EG; Mauss EA; Milot DC; Zucker MB
    J Cell Biochem; 1989 Apr; 39(4):339-54. PubMed ID: 2498343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 6-Keto-prostaglandin E1 inhibits the aggregation of human platelets.
    Wong PY; McGiff JC; Sun FF; Lee WH
    Eur J Pharmacol; 1979 Dec; 60(2-3):245-8. PubMed ID: 393526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of sodium citrate, low molecular weight heparin, and prostaglandin E1 on aggregation, fibrinogen binding, and enumeration of equine platelets.
    Kingston JK; Bayly WM; Sellon DC; Meyers KM; Wardrop KJ
    Am J Vet Res; 2001 Apr; 62(4):547-54. PubMed ID: 11327462
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Metabolism of intravenously administered prostaglandin E1 in patients with peripheral arterial occlusive disease].
    Hesse WH; Rudofsky G; Peskar BA
    Wien Klin Wochenschr; 1991; 103(18):554-7. PubMed ID: 1750222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of prostaglandin E1 during preparation of platelet concentrates.
    Hawker RJ; Turner VS; Mitchell SG
    Transfus Med; 1996 Sep; 6(3):249-54. PubMed ID: 8885155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of the effects of prostacyclin and 6-keto-prostaglandin E1 on renin release in the isolated rat and rabbit kidney.
    Schwertschlag U; Stahl T; Hackenthal E
    Prostaglandins; 1982 Jan; 23(1):129-38. PubMed ID: 7038776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Migraine: possible role of platelet insensitivity to prostaglandin E1 (PGE1).
    Cerneca F; de Luyk S; Radillo O; Simeone R; Mangiarotti M
    Funct Neurol; 1993; 8(6):403-8. PubMed ID: 8150318
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic phosphorylation of the focal adhesion-associated vasodilator-stimulated phosphoprotein in intact human platelets in response to cGMP- and cAMP-elevating platelet inhibitors.
    Nolte C; Eigenthaler M; Horstrup K; Hönig-Liedl P; Walter U
    Biochem Pharmacol; 1994 Oct; 48(8):1569-75. PubMed ID: 7980622
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interaction of prostaglandins E1 and E2 in regulation of cyclic-AMP and aggregation in human platelets: evidence for a common prostaglandin receptor.
    McDonald JW; Stuart RK
    J Lab Clin Med; 1974 Jul; 84(1):111-21. PubMed ID: 4365532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bioactive amide of prostaglandin E1 and ethanolamine plasmalogen analog of platelet-activating factor inhibits several pathways of human platelet aggregation.
    Kulikov VI; Muzya GI
    Biochemistry (Mosc); 2000 Apr; 65(4):427-30. PubMed ID: 10810178
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of aspirin and prostaglandin E1 on in vitro thrombolysis with urokinase. Evidence for a possible role of inhibiting platelet activity in thrombolysis.
    Terres W; Beythien C; Kupper W; Bleifeld W
    Circulation; 1989 Jun; 79(6):1309-14. PubMed ID: 2720929
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition by sodium nitroprusside or PGE1 of tyrosine phosphorylation induced in platelets by thrombin or ADP.
    Oda A; Druker BJ; Smith M; Salzman EW
    Am J Physiol; 1992 Mar; 262(3 Pt 1):C701-7. PubMed ID: 1372480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of adenyl-cyclase activators, phosphodiesterase inhibitors and pyridoxal-5-phosphate on platelet aggregation and adenosine-3'-5'-cyclic monophosphate accumulation.
    Zahavi M; Zahavi J; Kakkar VV
    Thromb Haemost; 1984 Oct; 52(2):205-9. PubMed ID: 6098048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.